Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NADK | O95544 | 2/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.53 |
| ▸ | PDE2A | O00408 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | HSPA8 | P11142 | 3/20 | 0.52 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GAPDH | P04406 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3878434 | 1.00 | NADK (0.54) | NADKADORA3ADORA2AADORA1PDE2A | |
| SCHEMBL14075812 | 1.00 | NADK (0.54) | NADKADORA3ADORA2AADORA1PDE2A | |
| SCHEMBL5706688 | 0.86 | NADK (0.54) | NADKADORA3ADORA2AHSPA8HSPA5 | |
| SCHEMBL27626941 | 0.86 | NADK (0.54) | NADKHSPA8HSPA5LMNATP53 | |
| SCHEMBL6439878 | 0.86 | NADK (0.54) | NADKHSPA8HSPA5LMNATP53 | |
| SCHEMBL5706686 | 0.86 | NADK (0.54) | NADKADORA3ADORA2AHSPA8HSPA5 | |
| SCHEMBL14075810 | 0.86 | HSPA8 (0.55) | ADORA3ADORA2AADORA1PDE2AADRA1A | |
| SCHEMBL5034818 | 0.86 | HSPA8 (0.55) | ADORA3ADORA2AADORA1PDE2AADRA1A | |
| SCHEMBL5034807 | 0.86 | HSPA8 (0.55) | ADORA3ADORA2AADORA1PDE2AADRA1A | |
| SCHEMBL13787727 | 0.82 | NADK (0.55) | NADKADORA3HSPA8HSPA5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221060-A1 | Adenosine derivatives for treatment of pain and/or inflammation; diabetes | BIOVITRUM AB (PUBL) (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221060-A1 | Adenosine derivatives for treatment of pain and/or inflammation; diabetes | BIOVITRUM AB (PUBL) (SE) | 2008-09-11 | — | — | US | disclosed |
| CN-1946732-A | Adenosine receptor agonists | CAMBRIDGE BIOTECHNOLOGY LTD (GB) | 2007-04-11 | — | — | CN | disclosed |
| EP-1749016-A2 | ADENOSINE RECEPTOR AGONISTS | Cambridge Biotechnology Ltd (GB) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005084653-A2 | ADENOSINE RECEPTOR AGONISTS | CAMBRIDGE BIOTECHNOLOGY LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| US-4990498-A | Tobacco mosaic virus | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1991-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221060-A1 | Adenosine derivatives for treatment of pain and/or inflammation; diabetes | ADORA3, ADORA2B, P2RX3 | NADK 1592/4885ADORA3 1/4885ADORA2A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.